Home » Authors » Kim Coghill

Kim Coghill

Articles

ARTICLES

Elan To Narrow Drug Focus, Tighten Governance Practice

June 11, 2002

Albany Molecular Enters Deal With Merck For Chemistry Work

June 10, 2002

Albany Molecular Enters Deal With Merck For Chemistry Work

June 10, 2002

Roche Invests $20M In Genmab In Expansion Of Antibody Alliance

June 7, 2002

Senators Seeking Compromise On Legislation To Ban Cloning

June 7, 2002

Roche Invests $20M In Genmab In Expansion Of Antibody Alliance

June 7, 2002

Senators Seeking Compromise On Legislation To Ban Cloning

June 7, 2002

Waksal Subpoenaed; ImClone To Face House Subcommittee

June 6, 2002

WASHINGTON - Former ImClone Systems Inc. CEO Samuel Waksal has been subpoenaed by a House subcommittee to answer questions surrounding the business transactions and development of the investigational cancer drug Erbitux. (BioWorld Today)

Waksal Subpoenaed; ImClone To Face House Subcommittee

June 6, 2002

WASHINGTON - Former ImClone Systems Inc. CEO Samuel Waksal has been subpoenaed by a House subcommittee to answer questions surrounding the business transactions and development of the investigational cancer drug Erbitux. (BioWorld Today)

Synthetic Blood Gains Access To $20M Equity Credit Line

June 4, 2002

View All Articles by Kim Coghill

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...